Achieve Life Sciences Announces Addition to the U.S. Russell 3000 and Russell Microcap Indexes
Achieve Life Sciences Announces Addition to the U.S. Russell 3000 and Russell Microcap Indexes
SEATTLE and VANCOUVER, British Columbia, July 01, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, announced that the company has been added to the U.S. Russell 3000 and Russell Microcap Indexes, which will be effective today, Monday, July 1, 2024, at the opening of the U.S. equity markets.
成就生命科學公司(Nasdaq: ACHV)是一家有承諾全球發展和商業化菸草戒斷和尼古丁依賴性藥品cytisinicline的後期製藥公司,該公司今天宣佈已被加入美國羅素3000全球貨幣指數。和羅素微小盤等指數。該指數即日起,也就是美國股票市場於2024年7月1日上午開盤時生效。
"We are proud to be included in the U.S. Russell 3000and Russell MicrocapIndexes and see this as an opportunity to enhance Achieve's visibility among investors," said John Bencich, Achieve's Chief Executive Officer. "This recognition reflects Achieve's solid business fundamentals and market potential for cytisinicline as a treatment for nicotine dependence. We are dedicated to advancing our strategic priorities to deliver value for our stakeholders and remain committed to addressing the worldwide crisis of smoking and nicotine vaping addiction. We are currently anticipating a new drug application submission for the treatment of smoking cessation in the United States in the first half of 2025."
成就生命科學公司首席執行官約翰·本奇表示:“我們很自豪被納入美國羅素3000全球貨幣指數的成分股,並視其爲提高成就在投資者中的知名度的機遇。此認可反映了成就雄厚的業務基礎和cytisinicline在尼古丁依賴性治療市場的巨大潛力。我們致力於推進戰略重點,爲股東創造價值,仍致力於解決全球的吸菸和尼古丁電子煙成癮危機。我們目前預期將於2025年上半年在美國遞交戒菸治療藥物申請。”美國羅素3000全球貨幣指數及適當的增長和價值指數成員資格是根據市場資本總值高低以及風格屬性等目標由富時羅素確認的。他們是一些投資經理及機構投資者制定指數基金以及作爲活躍投資策略的基準。除了入選美國羅素3000全球貨幣指數,成就生命科學公司最近還宣佈與硅谷銀行及其關聯公司(“SVB”)簽署了一份非約束性授信合同,以再融資和延長當前期限爲8月1日,2024年到期的優先貸款的到期日,貸款金額在$20,000,000之內。文件提供到2025年12月31日至少的按揭支付可伸縮取款額度,並於2025年6月1日到期。各方擬於2024年8月1日或之前關於再融資貸款達成協議,但該文件爲非約束性,公司不能確保能與SVB就文件提供的項任何條款進入到最終協議。
The Company also recently announced that it entered into a non-binding term sheet to refinance and extend the maturity date of its outstanding term loans with Silicon Valley Bank and its affiliates ("SVB"). The term sheet provides for a tranched facility amount of up to $20 million, maturing June 1, 2028, with interest-only payments through at least December 31, 2025. The parties anticipate closing on the refinanced loan on or before the current loan maturity date of August 1, 2024; however, the term sheet is non-binding, and there is no assurance that the Company will be able to enter into a definitive agreement with SVB on the terms provided in the term sheet, or any at all.
美國羅素指數每年實行重新配股,抓取截至2024年4月30日的4000個市值最大的美國股票,根據其總市值排序。入選美國羅素3000全球貨幣指數及適當的增長和價值指數,揭示出成就生命科學公司已取得顯著的經濟和政治成分。
About FTSE Russell
Russell U.S. indexes are reconstituted annually, capturing the 4,000 largest U.S. stocks as of April 30, 2024, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000 Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes, and are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.
關於FTSE Russell
成就主要集中於解決全球吸菸健康和尼古丁成癮的流行病,其通過開發和商業化cytisinicline來解決問題。僅在美國就有大約2800萬成年人吸食可燃香菸。目前,菸草使用是導致可預防死亡的主要原因,每年全球因此死亡800多萬人,美國近50萬人。87%以上的肺癌死亡,61%的肺疾病死亡和32%心臟病死亡都歸因於吸菸或暴露於二手煙。此外,美國有超過1100萬成年人使用電子煙,2023年大約有210萬中學和高中學生在美國使用電子煙。目前,沒有經FDA批准的治療電子煙尼古丁戒斷的特定藥物。cytisinicline是一種植物性生物鹼,其具有與膽鹼能受體非常高的結合親和力。該藥品通過與大腦中的受體相互作用,減輕戒斷症狀的嚴重程度,以及減少與尼古丁製品相關的獎勵和滿足感,有望對治療吸菸和電子煙成癮產生幫助作用。cytisinicline是一種正在開發的潛在產品候選,用於治療尼古丁成癮,未獲得美國FDA批准。了解更多cytisinicline和成就的詳情,請訪問。U.S.全市場Russell 3000指數的成員資格將持續一年,這意味着自動包含在大型Russell 1000指數或小型Russell 2000指數以及適當的成長和價值風格指數中。 FTSE Russell主要根據客觀的市值排名和風格屬性來確定其Russell指數的成員資格。年度Russell US指數重組捕獲了截至4月30日星期二的美國最大的4,000只股票,並按總市值排名。成爲美國全市場Russell 3000指數或小型市值Russell 2000指數以及適當的成長和價值風格指數的成員。本文包含根據1995年《私人證券訴訟改革法》的“安全港”規定所作的前瞻性陳述,包括但不限於加入美國羅素3000全球貨幣指數和羅素迷你市值指數的影響、cytisinicline臨床開發和監管申報的時間和性質、cytisinicline的市場規模潛力以及cytisinicline的潛在受益。除歷史事實陳述外,其他所有說明均可被視爲前瞻性陳述。成就未必能夠按時或根本實現其計劃或產品開發目標,或者其意圖,或滿足其在這些前瞻性陳述所披露的期望或預測。這些說明是基於管理層的現有期望和信念,並且帶有一定的風險、不確定性和假設,這些風險、不確定性和假設可能導致實際結果與前瞻性陳述描述不符,包括但不限於cytisinicline未能證明爲具有預期功效或效益的風險;成就可能無法獲得資金支持以用於cytisinicline的開發;cytisinicline可能無法取得監管批准或成功商業化;在戒菸領域的新發展可能要求業務策略或臨床開發計劃發生變更的風險;成就的知識產權可能無法得到充分保護;一般商業和經濟條件;與大宏觀經濟和地緣政治條件對企業的影響,包括通貨膨脹、利率上升、債券和股票市場的波動加劇,全球銀行系統的實際或被視爲不穩定,全球衛生危機、大流行病和地緣政治衝突,以及美國證券交易委員會不時有關風險因素的申報,其中包括Achieve的10-K年度報告和10-Q季度報告。除法律法規另有規定外,成就無義務更新本學報中所述的前瞻性陳述,以反映本學報日期之後發生的事件或情況。
For more information on the Russell 3000, Russell Microcap Indexes, and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.
有關Russell 3000指數和Russell指數重組的更多信息,請訪問FTSE Russell網站上的“Russell Reconstitution”部分。了解有關美國羅素3000全球貨幣指數、羅素微型指數和羅素重配的更多信息,請訪問富時羅素網站上的“Achieve Reconstitution”部分。
About Achieve and Cytisinicline
Achieve's focus is to address the global smoking health and nicotine addiction epidemic through the development and commercialization of cytisinicline. There are an estimated 28 million adults in the United States alone who smoke combustible cigarettes.1 Tobacco use is currently the leading cause of preventable death that is responsible for more than eight million deaths worldwide and nearly half a million deaths in the United States annually.2,3 More than 87% of lung cancer deaths, 61% of all pulmonary disease deaths, and 32% of all deaths from coronary heart disease are attributable to smoking and exposure to secondhand smoke.3
成就的重點是通過開發和商業化cytisinicline來解決全球吸菸健康和尼古丁成癮的流行病。僅在美國就有大約2800萬成年人吸食可燃香菸。
菸草使用目前是導致可預防死亡的主要原因,每年全球因此死亡800多萬人,美國近50萬人。1超過87%的肺癌死亡、61%的肺疾病死亡和32%的冠心病死亡都歸因於吸菸或暴露於二手煙。2,3此外,美國有超過1100萬成年人使用電子煙,2023年大約有210萬中學和高中學生在美國使用電子煙。3
In addition, there are over 11 million adults in the United States who use e-cigarettes, also known as vaping.1 In 2023, approximately 2.1 million middle and high school students in the United States reported using e-cigarettes.4 Currently, there are no FDA-approved treatments indicated specifically as an aid to nicotine e-cigarette cessation.
目前,沒有經FDA批准的治療電子煙尼古丁戒斷的特定藥物。1cytisinicline是一種植物性生物鹼,通過與大腦中的受體相互作用,減輕戒斷症狀的嚴重程度,以及減少與尼古丁製品相關的獎勵和滿足感,有望對治療吸菸和電子煙成癮產生幫助作用。cytisinicline是一種正在開發的潛在產品候選,用於治療尼古丁成癮,未獲得美國FDA批准。了解更多cytisinicline和成就的詳情,請訪問。4目前,沒有經FDA批准的治療電子煙尼古丁戒斷的特定藥物。
Cytisinicline is a plant-based alkaloid with a high binding affinity to the nicotinic acetylcholine receptor. It is believed to aid in treating nicotine addiction for smoking and e-cigarette cessation by interacting with nicotine receptors in the brain, reducing the severity of withdrawal symptoms, and reducing the reward and satisfaction associated with nicotine products. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine addiction and has not been approved by the Food and Drug Administration for any indication in the United States. For more information on cytisinicline and Achieve visit .
cytisinicline是一種植物性生物鹼,通過與大腦中的受體相互作用,減輕戒斷症狀的嚴重程度,以及減少與尼古丁製品相關的獎勵和滿足感,有望對治療吸菸和電子煙成癮產生幫助作用。cytisinicline是一種正在開發的潛在產品候選,用於治療尼古丁成癮,未獲得美國FDA批准。了解更多cytisinicline和成就的詳情,請訪問。
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the effects of being added to the U.S. Russell 3000 and Russell Microcap Indexes, the timing and nature of cytisinicline clinical development and regulatory submissions, the potential market size for cytisinicline, and the potential benefits of cytisinicline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, among others, the risk that cytisinicline may not demonstrate the hypothesized or expected benefits; the risk that Achieve may not be able to obtain additional financing to fund the development of cytisinicline; the risk that cytisinicline will not receive regulatory approval or be successfully commercialized; the risk that new developments in the smoking cessation landscape require changes in business strategy or clinical development plans; the risk that Achieve's intellectual property may not be adequately protected; general business and economic conditions; risks related to the impact on our business of macroeconomic and geopolitical conditions, including inflation, rising interest rates, increased volatility in the debt and equity markets, actual or perceived instability in the global banking system, global health crises and pandemics and geopolitical conflict and the other factors described in the risk factors set forth in Achieve's filings with the Securities and Exchange Commission from time to time, including Achieve's Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable.
前瞻性聲明
本新聞稿包含根據1995年《私人證券訴訟改革法》"安全港"規定的前瞻性聲明,包括但不限於有關加入美國羅素3000和羅素微型股指數的影響、cytisinicline臨床研究和監管提交的時機和性質、cytisinicline潛在市場規模以及cytisinicline潛在益處的陳述。所有非歷史事實陳述都可能被視爲前瞻性陳述。如果有的話,Achieve可能無法按時或根本無法實現其計劃或產品開發目標,或無法實現其在這些前瞻性陳述中披露的意圖或滿足其期望或預測。這些陳述基於管理層當前的期望和信念,並且受到許多風險、不確定性和假設的影響,這些風險、不確定性和假設可能導致實際結果與前瞻性陳述所描述的結果有很大的區別,包括但不限於cytisinicline可能無法展示其假設或預期的益處的風險;Achieve可能無法獲得其他融資來資助cytisinicline的開發的風險;cytisinicline將無法獲得監管批准或成功商業化的風險;在吸菸戒斷領域的新進展需要更改業務策略或臨床開發計劃的風險;Achieve的知識產權可能沒有得到充分保護的風險;普通商業和經濟情況風險;與宏觀經濟和地緣政治狀況對我們業務的影響有關的風險,包括通貨膨脹、利率上升、債券和股票市場波動加劇、全球銀行體系實際或被認爲不穩定、全球健康危機和大流行病以及地緣政治衝突,以及在Achieve不時向證券交易委員會提交的風險因素中所述的其他因素,包括Achieve的10-K年度報告和10-Q季度報告。Achieve沒有義務更新此處所包含的前瞻性陳述或反映此後發生的事件或情況,除非適用法律要求其這樣做。及羅素Microcap指數、cytisinicline的臨床開發和監管提交的時機和性質、cytisinicline的潛在市場規模以及cytisinicline的潛在益處。所有非歷史事實陳述都可能被認定爲前瞻性陳述。如果有的話,Achieve可能無法按時或根本無法實現其計劃或產品開發目標,或無法實現其在這些前瞻性陳述中披露的意圖或滿足其期望或預測。這些陳述基於管理層當前的期望和信念,並受到許多風險、不確定性和假設的影響,這些風險、不確定性和假設可能導致實際結果與前瞻性陳述所描述的結果有很大的區別,包括但不限於cytisinicline可能無法展示其假設或預期的益處的風險;Achieve可能無法獲得其他融資來資助cytisinicline的開發的風險;cytisinicline將無法獲得監管批准或成功商業化的風險;在吸菸戒斷領域的新進展需要更改業務策略或臨床開發計劃的風險;Achieve的知識產權可能沒有得到充分保護的風險;普通商業和經濟情況風險;與宏觀經濟和地緣政治狀況對我們業務的影響有關的風險,包括通貨膨脹、利率上升、債券和股票市場波動加劇、全球銀行體系實際或被認爲不穩定、全球健康危機和大流行病以及地緣政治衝突,以及在Achieve不時向證券交易委員會提交的風險因素中所述的其他因素,包括Achieve的10-K年度報告和10-Q季度報告。Achieve沒有義務更新此處所包含的前瞻性陳述或反映此後發生的事件或情況,除非適用法律要求其這樣做。蘋果首席執行官庫克批量拋售股票,套現超過3億港元。
Investor Relations Contact
Nicole Jones
achv@cg.capital
(404) 736-3838
投資者關係聯繫人
Nicole Jones
achv@cg.capital
(404) 736-3838
Media Contact
Glenn Silver
Glenn.Silver@Finnpartners.com
(646) 871-8485
媒體聯繫人
Glenn Silver
Glenn.Silver@Finnpartners.com
(646) 871-8485
References
1Cornelius ME, Loretan CG, Jamal A, et al. Tobacco Product Use Among Adults – United States, 2021. MMWR Morb Mortal Wkly Rep 2023;72:475–483.
2World Health Organization. WHO Report on the Global Tobacco Epidemic, 2019. Geneva: World Health Organization, 2017.
3U.S. Department of Health and Human Services. The Health Consequences of Smoking – 50 Years of Progress. A Report of the Surgeon General, 2014.
4Birdsey J, Cornelius M, Jamal A, et al. Tobacco Product Use Among U.S. Middle and High School Students — National Youth Tobacco Survey, 2023. MMWR Morb Mortal Wkly Rep 2023;72:1173–1182.
參考
1Cornelius ME,Loretan CG,Jamal A等。2021年美國成年人使用菸草產品的情況。MMWR Morb Mortal Wkly Rep 2023年;72:475–483。
2世界衛生組織。2019全球菸草流行病報告。日內瓦:世界衛生組織,2017年。
3美國衛生與公衆服務部。吸菸的健康後果-50年的進展。全美醫生協會,2014年。
4Birdsey J,Cornelius M,Jamal A等。2023年全國青少年使用菸草產品的中小學生調查。MMWR Morb Mortal Wkly Rep 2023;72:1173–1182。